AQU 005

Drug Profile

AQU 005

Alternative Names: AQU-005; NM-AQU-005

Latest Information Update: 08 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aquilus Pharmaceuticals
  • Developer NeuroMax
  • Class Small molecules
  • Mechanism of Action Matrix metalloproteinase 2 inhibitors; Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 29 Jun 2016 Phase-I clinical trials in Neuropathic pain in Russia (unspecified route)
  • 24 Jun 2013 Preclinical trials in Neuropathic pain in Russia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top